## II. AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of treating or preventing discomfort, unpleasant symptons, irritation, or pain associated with a tissue, the method comprising contacting the tissue with a pharmaceutical, dermatological or cosmetic composition or a medical device comprising a therapeutically effective an amount of a biocompatible polymer corresponding to one of the formulas selected from the group consisting of following general formula (I):

in which:

A represents comprises a monomer that is glucose,

X represents a RCOOR' group,

Y represents an O or N-sulphonate group bound to A,

R represents an aliphatic <u>a</u> hydrocarbon chain, possibly branched and/or unsaturated and which may contain one or more aromatic rings and R' represents one hydrogen atom or one cation,

a represents the number of monomers,

x represents the rate of substitution of the A monomers by the X groups, and x is between approximately 20 and 150%.

y represents the rate of substitution of the A monomers by Y groups, <u>and</u> <u>y is between approximately 30 and 150%;</u>

wherein the biocompatible polymer is in an amount effective to treat pain and wherein the method does not treat the condition that causes the pain.

2. (Currently Amended) The method of claim 1, in which the A <u>further comprises</u> monomers, identical or different, [[are]] selected from <u>the group consisting of: among sugars</u>, esters, alcohols, amino acids, nucleotides, nucleic acids or proteins.

Application No. 10/577,637 Reply to Office Action of March 4, 2010 Docket No.: 021305-00321

- 3. (Currently Amended) The method of claim 1, wherein the mass of the polymers of formula (I) is greater than approximately 2000 daltons.
  - 4. (Cancelled).
  - 5. (Cancelled).
- 6. (Previously Presented) The method of claim 1, wherein the radical R is a linear or branched alkyl, allyl or aryl group.
- 7. (Currently Amended) The method of claim 1, wherein the biocompatible polymer comprises functional chemical groups Z, different from X and Y and capable of bestowing additional biological or physical and chemical properties on the said polymers, wherein said Z groups are identical or different and are amino acids, fatty acids, fatty alcohols, ceramides or derivatives thereof, or nucleotide sequences.
- 8. (Previously Presented) The method of claim 7, wherein the rate of substitution of all the A monomers by Z groups represented by "z" is between 0 and 50%.
- 9. (Previously Presented) The method of claim 7, wherein the Z group is a substance capable of bestowing on the said polymers improved solubility or lipophilia.
  - 10. (Cancelled).
- 11. (Previously Presented) The method of claim 7, wherein the Z groups are identical or different and are therapeutic agents.
- 12. (Currently Amended) The method of claim 1, wherein the pharmaceutical or dermatological composition or the medical device are intended to prevent, relieve and/or treat pains and/or itching pain is induced by lesions or irritations in an individual in an area in contact with an outside medium.

- (Previously Presented) The method of claim 12, wherein the lesions or 13. irritations are selected among skin lesions, corneal lesions, lesions of the eardrum, lesions of the digestive tract, lesions of the respiratory tract such as lesions of the tissues of the airways and lungs and lesions of the urogenital tract.
- (Currently Amended) The method of claim 1, wherein the pharmaceutical 14. or dermatological composition or the medical device is intended to prevent, relieve and/or treat pains pain is in the tendons and/or cartilages and/or the joints and/or the back and/or the muscles and in general, following impact and/or diffuse pains in the abdomen or in the head.
- (Currently Amended) The method of claim 1, comprising contacting the 15. skin with a cosmetic composition for prevention and relief of tingling, irritation, itching or pulling treatment of pain associated with the skin, cornea or mucosae.
- 16. (Currently Amended) The method of claim 1, wherein the pharmaceutical or dermatological composition or the medical device is intended to prevent, relieve and/or treat

- the pa	the pain <del>and/or pruritus</del> <u>is</u> induced by						
*	deep skin burns;						
*	scars and cicatricial tissue;						
*	ulcers of the skin and/or the mucosae and/or the cornea;						
*	peripheral and/or degenerative neuropathies;						
*	cold sores;						
*	chapping;						
*	hyperkeratinisation of the skin, psoriasis, eczema or herpes zoster;						
*	a surgical operation;						
*	radiotherapy;						
*	a lesion of the eardrum;						
*	asthma and/or rhinitis and/or bronchial obstruction;						
*	aphthous ulcers and/or sore throats and/or dental pains; or						
ntion No. 10/577.6	37 Docket No.: <b>021305-00321</b>						

Application No. 10/577,637

Reply to Office Action of March 4, 2010

		*	arthroses or	arthritis <del>;</del>						
	- irritation of the mucosae and/or the skin; or									
	***************************************	chron	ic diseases	characterised	-by-	destruction	and/or	<del>permanent</del>		
remodelling of the extracellular matrix.										
17.	(Cano	elled).								

Application No. 10/577,637 Reply to Office Action of March 4, 2010

Docket No.: 021305-00321